J V Selby1, G T Ray, D Zhang, C J Colby. 1. Division of Research, Kaiser Permanente Medical Care Program, Oakland, CA 94611, USA.
Abstract
OBJECTIVE: To estimate the excess costs of medical care for patients with diabetes in a managed care population and to determine the proportion of costs spent on treating the complications of diabetes. RESEARCH DESIGN AND METHODS: A comparison of 1-year (1994) costs of medical care in the 85,209 members of the diabetes registry of Kaiser Permanente, Northern California, and in 85,209 age- and sex-matched nondiabetic control subjects. Costs were obtained from automated program databases. Costs specifically related to treating acute and long-term complications of diabetes were identified, and the excess costs attributable to each complication in individuals with diabetes were calculated. RESULTS: Excess expenditures in individuals with diabetes totaled $282.7 million, or $3,494 per person. Per person expenditures for members with diabetes were 2.4 times those for matched control subjects. The largest proportion of total excess costs was for hospitalizations within the health maintenance organization (38.5%). Nearly 38% of the total excess was spent treating the long-term complications of diabetes, predominantly coronary heart disease and end-stage renal disease. CONCLUSIONS: Diabetes is a costly condition by virtue of its high prevalence and high per person costs. A large proportion of these costs are related to treating complications of diabetes. Available evidence indicates that several measures can reduce complication rates. Thus, effective disease management programs that aim to prevent complications could potentially lead to cost savings in managed care settings.
OBJECTIVE: To estimate the excess costs of medical care for patients with diabetes in a managed care population and to determine the proportion of costs spent on treating the complications of diabetes. RESEARCH DESIGN AND METHODS: A comparison of 1-year (1994) costs of medical care in the 85,209 members of the diabetes registry of Kaiser Permanente, Northern California, and in 85,209 age- and sex-matched nondiabetic control subjects. Costs were obtained from automated program databases. Costs specifically related to treating acute and long-term complications of diabetes were identified, and the excess costs attributable to each complication in individuals with diabetes were calculated. RESULTS: Excess expenditures in individuals with diabetes totaled $282.7 million, or $3,494 per person. Per person expenditures for members with diabetes were 2.4 times those for matched control subjects. The largest proportion of total excess costs was for hospitalizations within the health maintenance organization (38.5%). Nearly 38% of the total excess was spent treating the long-term complications of diabetes, predominantly coronary heart disease and end-stage renal disease. CONCLUSIONS:Diabetes is a costly condition by virtue of its high prevalence and high per person costs. A large proportion of these costs are related to treating complications of diabetes. Available evidence indicates that several measures can reduce complication rates. Thus, effective disease management programs that aim to prevent complications could potentially lead to cost savings in managed care settings.
Authors: Lori C Sakoda; Assiamira Ferrara; Ninah S Achacoso; Tiffany Peng; Samantha F Ehrlich; Charles P Quesenberry; Laurel A Habel Journal: Cancer Prev Res (Phila) Date: 2015-02
Authors: Edward W Gregg; Andrew J Karter; Robert B Gerzoff; Monika Safford; Arleen F Brown; Chien-Wen Tseng; Beth Waitzfielder; William H Herman; Carol M Mangione; Joseph V Selby; Theodore J Thompson; R Adams Dudley Journal: Med Care Date: 2010-01 Impact factor: 2.983
Authors: Kristi Reynolds; Alan S Go; Thomas K Leong; Denise M Boudreau; Andrea E Cassidy-Bushrow; Stephen P Fortmann; Robert J Goldberg; Jerry H Gurwitz; David J Magid; Karen L Margolis; Catherine J McNeal; Katherine M Newton; Rachel Novotny; Charles P Quesenberry; Wayne D Rosamond; David H Smith; Jeffrey J VanWormer; Suma Vupputuri; Stephen C Waring; Marc S Williams; Stephen Sidney Journal: Am J Med Date: 2016-10-14 Impact factor: 4.965
Authors: Tiffany Y Peng; Samantha F Ehrlich; Yvonne Crites; John L Kitzmiller; Michael W Kuzniewicz; Monique M Hedderson; Assiamira Ferrara Journal: Am J Obstet Gynecol Date: 2016-10-15 Impact factor: 8.661
Authors: Thomas Songer; Judith Glazner; Laura P Coombs; Leona Cuttler; Mary Daniel; Silvia Estrada; Georgeanna Klingensmith; Andrea Kriska; Lori Laffel; Ping Zhang Journal: Expert Rev Pharmacoecon Outcomes Res Date: 2006-06-01 Impact factor: 2.217
Authors: Elbert S Huang; Andrew J Karter; Kirstie K Danielson; E Margaret Warton; Ameena T Ahmed Journal: J Gen Intern Med Date: 2009-12-05 Impact factor: 5.128